Search
Powered By HealthLine
Health Tools
 Menopause Introduction
 STD Symptoms
 Your Love Life
 Sex Tips & Advice
 STD Prevention
 Ask The Gynecologist
 Safe Sex & STDs
 The Basics of Herpes
 Solve A Sexual Problem
 Herpes Q&A
 The Basics of ED
Featured Conditions
 Breast Cancer
 Erectile Dysfunction
 Menopause
 Incontinence
 Skin Care
 Food & Fitness
 Herpes
 Sexual Health
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & Precautions
Clinical PharmacologyOverdosage & ContraindicationsIndications & Dosage

Avandia

[Rosiglitazone maleate]

In monkeys, rosiglitazone (0.6 and 4.6 mg/ kg/ day; approximately 3 and 15 times human AUC at the maximum recommended human daily dose, respectively) diminished the follicular phase rise in serum estradiol with consequential reduction in the luteinizing hormone surge, lower luteal phase progesterone levels, and amenorrhea. The mechanism for these effects appears to be direct inhibition of ovarian steroidogenesis.

Animal Toxicology:

Heart weights were increased in mice (3 mg/ kg/ day), rats (5 mg/ kg/ day), and dogs (2 mg/ kg/ day) with rosiglitazone treatments (approximately 5, 22, and 2 times human AUC at the maximum recommended human daily dose, respectively). Morphometric measurement indicated that there was hypertrophy in cardiac ventricular tissues, which may be due to increased heart work as a result of plasma volume expansion.

Text Continues Below



Pregnancy:

Pregnancy Category C:

There was no effect on implantation or the embryo with rosiglitazone treatment during early pregnancy in rats, but treatment during mid-late gestation was associated with fetal death and growth retardation in both rats and rabbits.

Teratogenicity was not observed at doses up to 3 mg/ kg in rats and 100 mg/ kg in rabbits (approximately 20 and 75 times human AUC at the maximum recommended human daily dose, respectively). Rosiglitazone caused placental pathology in rats (3 mg/ kg/ day). Treatment of rats during gestation through lactation reduced litter size, neonatal viability, and postnatal growth, with growth retardation reversible after puberty. For effects on the placenta, embryo/ fetus, and offspring, the no-effect dose was 0.2 mg/ kg/ day in rats and 15 mg/ kg/ day in rabbits. These no-effect levels are approximately 4 times human AUC at the maximum recommended human daily dose.

There are no adequate and well-controlled studies in pregnant women. AVANDIA should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

Because current information strongly suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital anomalies as well as increased neonatal morbidity and mortality, most experts recommend that insulin monotherapy be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Labor and Delivery

The effect of rosiglitazone on labor and delivery in humans is not known.

Nursing Mothers

Drug-related material was detected in milk from lactating rats. It is not known whether AVANDIA is excreted in human milk. Because many drugs are excreted in human milk, AVANDIA should not be administered to a nursing woman.

Page:  << Prev | 1 | 2 | 3 | 4 | 5







HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2013. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire